| | Mental Health | Schizophrenia
Long-Term Antipsychotic Treatment in Schizophrenia: Necessity, Reduction, and Shared Decision-Making
Evidence-Based Consensus
Most patients with schizophrenia require indefinite antipsychotic maintenance to prevent relapse. Relapse rates off medication: ~70–80% at 1 year vs. ~20–30% on maintenance.
Guided Dose Reduction / Discontinuation Attempts
May be considered only under close psychiatric supervision if:
- Sustained remission ≥2–5 years (first episode: longer).
- Patient strongly desires trial; understands risks.
- Robust psychosocial support, early warning plan, rapid re-access to care.
- Slow taper (months); monitor weekly initially.
Risks of Discontinuation
- Relapse → hospitalization, functional decline, treatment resistance.
- Suicide risk increases during psychotic relapse.
- Neuroprogression hypothesis: each episode may cause subtle brain changes.
- Loss of insight (anosognosia) delays recognition of relapse.
Shared Decision-Making Framework
- Discuss evidence, values, preferences.
- Define "remission" criteria (symptom scales, functioning).
- Agree on taper schedule, monitoring frequency, relapse criteria.
- Document plan; involve family/support (with consent).
- Re-evaluate regularly—resume medication promptly if early signs emerge.
Never stop antipsychotics abruptly. Always consult your psychiatrist.
Schizophrenia - Related Articles
- Preexisting Psychosis & Cannabis: Risks & Clinical Guidance
- Geodon (Ziprasidone): Side Effects, Uses & Warnings
- Narcissism and Hidden Insecurity: Understanding the Paradox
- Schizophrenia: Biological Mechanisms and Treatment Implications
- Lorazepam for Schizophrenia: Uses, Benefits & Considerations
- CBT for Schizophrenia: A Comprehensive Guide to Treatment
- Understanding Childhood Schizophrenia: Symptoms & Signs
